Pfizer Settles Protonix Off-Label Allegations – Pricing Investigation Still Unresolved
This article was originally published in The Pink Sheet Daily
Pfizer finalizes a $55 million settlement with the Department of Justice concerning Wyeth’s Protonix promotional practices; a separate probe of alleged bundling of Protonix sales to hospitals continues.
You may also be interested in...
Pfizer Protonix Settlement May Deter Price Bundling
$784.6m fine will resolve claims that Wyeth subsidiary paid hospitals steep discounts if they purchased both oral and IV Protonix while reporting higher prices to the government.
Under DOJ’s Microscope: Teva Is Latest Company To Face Government Probe
AstraZeneca, Merck, Novartis and Sanofi are also under investigation for potential health care fraud.
Off-Label Prosecutions Hinge On Patient Benefit, Government Attorneys Say
Federal prosecutors say they will not pursue False Claims Act cases in which off-label use is the standard of care and note that the Caronia decision will have little impact on investigations; First Amendment defense fails in Par and Harkonen cases.